en.as.com
These are the drugs that lose their U.S. patents in 2025: most are in common use across the country by millions of people
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because insurance coverage or pharmacy supply could change.
Adult patients with Crohn’s disease or ulcerative colitis who use biologic therapies, clinicians who prescribe these drugs, pharmacists, and patients interested in medication costs or biosimilars.
What To Know
This article lists major drugs losing U.S. patent protection in 2025 and names several medicines used in IBD care (notably Stelara, Simponi/Simponi Aria, and Tysabri). Expect increased competition from biosimilars as exclusivity ends, which can affect availability and cost over time.
Patent expirations mean manufacturers can face generic or biosimilar competition. For IBD patients, that often leads to new biosimilars entering the market for biologic therapies such as ustekinumab (Stelara), golimumab (Simponi), and natalizumab (Tysabri).
These market changes can influence drug pricing, insurance coverage, and treatment options but do not directly change how these drugs are used clinically.
If you are on any of the drugs mentioned, talk with your care team or pharmacist before making any changes; switching to a biosimilar is a clinical decision involving efficacy, safety, and insurance considerations.
Keep an eye on insurer communications and FDA/biosimilar approvals over the coming months, since product launches and coverage decisions follow patent expirations.
This is a news roundup about patent expirations compiled from industry reporting. Patent loss is a market/legal event; biosimilar availability, FDA approvals, pricing, and payer policies determine real-world access and timing. This article does not report new clinical trial results or guidance about switching therapies.
